Travere Therapeutics (TVTX) to Release Quarterly Earnings on Monday

Travere Therapeutics (NASDAQ:TVTX) will issue its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The firm had revenue of $45.06 million during the quarter, compared to analyst estimates of $41.25 million. On average, analysts expect Travere Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Stock Up 1.6 %

Shares of NASDAQ:TVTX opened at $6.26 on Friday. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $19.54. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. The firm has a market capitalization of $476.45 million, a P/E ratio of -3.83 and a beta of 0.69. The stock has a 50 day moving average price of $7.10 and a 200-day moving average price of $7.61.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Piper Sandler raised their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th. Guggenheim reaffirmed a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. HC Wainwright increased their target price on Travere Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Wells Fargo & Company increased their target price on Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Finally, Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.